Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAyflOwer RoAD: Sembragiline in Moderate Alzheimer's Disease
NCT01677754Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 2012
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of sembragiline in Alzheimer's disease (AD), sponsored by Roche. Started Oct 2012; status: completed.
02
Drugs
sembragiline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01677754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01677754.